Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...
Patients requiring intraoperative conversion from robotic-assisted radical cystectomy to open surgery have higher 90-day mortality rates and 30-day readmission rates. Intraoperative conversion from ...
Radical cystectomy continues to have an important role in the management of recurrent high-grade NMIBC, according to results from the CISTO study. The CISTO study assessed patient-important outcomes ...
PATIENTS AND METHODS: All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July 1971 ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...
The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...
A 30-day course of prophylactic antibiotics following robot-assisted radical cystectomy significantly reduces the incidence of urinary tract infections (UTIs) and related complications, researchers ...
Treatment recommendations for all stages of bladder cancer have been proposed in the form of clinical guidelines from the European Association of Urology and the American Urological Association.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback